Growth Metrics

Nektar Therapeutics (NKTR) Depreciation & Amortization (CF) (2016 - 2025)

Nektar Therapeutics has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $190000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $190000.0 for Q4 2025, down 42.77% from a year ago — trailing twelve months through Dec 2025 was $960000.0 (down 68.53% YoY), and the annual figure for FY2025 was $1.0 million, down 76.63%.
  • Depreciation & Amortization (CF) for Q4 2025 was $190000.0 at Nektar Therapeutics, up from $163000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for NKTR hit a ceiling of $3.7 million in Q1 2022 and a floor of $163000.0 in Q3 2025.
  • Median Depreciation & Amortization (CF) over the past 5 years was $1.9 million (2023), compared with a mean of $2.0 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 11.56% in 2021 and later crashed 79.9% in 2024.
  • Nektar Therapeutics' Depreciation & Amortization (CF) stood at $3.4 million in 2021, then fell by 7.39% to $3.2 million in 2022, then tumbled by 48.08% to $1.7 million in 2023, then crashed by 79.9% to $332000.0 in 2024, then plummeted by 42.77% to $190000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $190000.0 (Q4 2025), $163000.0 (Q3 2025), and $181000.0 (Q2 2025) per Business Quant data.